BioAge's chances slimmer after obesity failure

9 December 2024

Monday looks likely to be a tough day for BioAge Labs (Nasdaq: BIOA), a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.

Shares in BioAge were 70% lower in pre-market trading after the Californian company announced the discontinuation of the ongoing STRIDES Phase II study.

The trial has been investigating BioAge’s drug candidate azelaprag as monotherapy and in combination with Eli Lilly’s (NYSE: LLY) Mounjaro/Zepbound (tirzepatide) after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK